Trials / Completed
CompletedNCT02329860
Study of Apatinib After Systemic Therapy in Patients With Hepatocellular Carcinoma(AHELP)
A Randomized, Double Blind, Placebo Controlled, Multicenter Phase III Study (AHELP) of Apatinib in Patients With Hepatocellular Carcinoma After Systemic Therapy（Chemotherapy and/or Targeted Therapy）
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 400 (actual)
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This was a multicenter, randomized, double-blind, phase III trial. This clinical study evaluates the efficacy and safety of Apatinib in patients with advanced liver cancer who have progressed on Systemic Therapy (Chemotherapy and/or Targeted Therapy). Approximately 400 patients who meet the entry criteria will be randomly assigned in a 2:1 ratio to Apatinib or placebo (1/3 chance to receive placebo). Primary endpoint of the study is overall survival.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Apatinib | |
| DRUG | Placebo |
Timeline
- Start date
- 2014-03-26
- Primary completion
- 2017-12-15
- Completion
- 2019-08-14
- First posted
- 2015-01-01
- Last updated
- 2024-01-22
- Results posted
- 2024-01-22
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02329860. Inclusion in this directory is not an endorsement.